XOMA Corporation ( XOMA ) recently announced that it intends to include active non-infectious anterior scleritis in the gevokizumab proof-of-concept program. Non-infectious anterior
XOMA Corporation ( XOMA ) recently announced that it intends to include active non-infectious anterior scleritis in the gevokizumab proof-of-concept program. Non-infectious anterior